Title	Published	Price
Special Report: Thought-Leader Opinion on the Current and Future Landscape of the Age-Related Macular Degeneration Market By: Decision Resources ... is the leading cause of irreparable vision loss in the United States. Interviewed U.S. experts indicate substantial unmet needs in current AMD treatment. With only a few approved therapies, this market presents a big opportunity ... \| more...	12/7/2011	$9,200.00
Special Report: Market Opportunities in Symptomatic Treatments of Multiple Sclerosis By: Decision Resources ... up the crop of new niche agents in the United States indicated specifically for the treatment of individual symptoms that commonly occur in patients with this chronic disease. Although these agents are available, demand for ... \| more...	12/7/2011	$9,200.00
Special Report: Patterns of Generic Erosion: An International Chartbook By: Decision Resources ... of ten drugs-five cardiometabolic agents and five central nervous system (CNS) therapies-that have lost market exclusivity in recent years shows enormous variations in originator brands' market share in the United States and the five largest ... \| more...	12/1/2011	$9,200.00
Special Report: Chartbook of International Pharmaceutical Prices By: Decision Resources ... be aware of international price differentials. Many studies have compared retail prices in different countries, but international comparisons of pharmaceutical prices at the ex-manufacturer level are relatively uncommon. This chartbook-our eighth annual analysis of international ... \| more...	12/1/2011	$9,200.00
Market-Changing Emerging Agents, 2012: The Evolving Blockbuster Model By: Decision Resources ... foresees five agents reaching the market in 2012 that will earn blockbuster sales (sales of $1 billion annually) at some point in the next five years. Our profiles of these drugs highlight the marketplace characteristics ... \| more...	12/1/2011	$4,600.00
Assessing the U.S. Regulatory Landscape for Diagnostic Testing By: Decision Resources ... emerge. However, some recent changes have caused a fair amount of controversy among industry and researchers alike. The ability of regulators and stakeholders to reconcile their differences will be key to the industry's continuing advancement. ... \| more...	12/1/2011	$4,600.00
Factors Influencing Morbidity Trends in BRIC Countries By: Decision Resources ... population dynamics and demographic changes (including urbanization), smoking and obesity are two key factors that will drive morbidity trends in Brazil, Russia, India, and China (the "BRIC" countries). Questions Answered Emerging markets, particularly the BRIC ... \| more...	12/1/2011	$4,600.00
Pharmaceutical Pricing, Reimbursement, and Market Access in Argentina By: Decision Resources ... for outsiders. Foreign companies need to understand the structure of the Argentine healthcare system, the limitations of intellectual property protection, pricing trends, and coverage policies for prescription drugs. In addition, multinationals must be prepared for ... \| more...	12/1/2011	$4,600.00
The Developing Life Sciences Industries of China and India By: Decision Resources ... India. Growth in this sector is in turn promoting innovative drug development, both by local pharmaceutical companies and by emerging biotechnology firms. As this industry sector develops, many local players will turn to MPCs for ... \| more...	12/1/2011	$4,600.00
Special Report: Lessons Learned in Emerging Pharmaceutical Markets, 2011 By: Decision Resources ... last decade. In contrast, in 2011, Big Pharma was plagued by (1) an austere economic landscape that negatively impacted the growth of mature pharmaceutical markets, (2) high levels of patent expiration and generics erosion, and ... \| more...	12/1/2011	$9,200.00
There Is an Urgent Need for More Efficacious High-Grade Glioma Treatments, but Will the Current Therapeutic Pipeline Suffice? By: Decision Resources ... last decade, and there is a pressing need for efficacious therapies that are both safe and tolerable. The role of Roche's Avastin (bevacizumab) in GBM is still debated, and the results of ongoing pivotal studies ... \| more...	12/1/2011	$4,600.00
Industry Outlook: Trends in Respiratory Disease Strategies By: Decision Resources ... on the cardiac safety of metabolic agents. Emerging therapies such as Orexigen/Takeda's Contrave, Abbott's Meridia, and GlaxoSmithKline's Avandia all have recently faced intense regulatory scrutiny over their cardiovascular safety profiles. Although drug development guidelines for ... \| more...	11/1/2011	$4,600.00
The Impact of Cardiac Safety on the Regulatory Landscape: Recent Case Studies By: Decision Resources ... on the cardiac safety of metabolic agents. Emerging therapies such as Orexigen/Takeda's Contrave, Abbott's Meridia, and GlaxoSmithKline's Avandia all have recently faced intense regulatory scrutiny over their cardiovascular safety profiles. Although drug development guidelines for ... \| more...	11/1/2011	$4,600.00
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Third Quarter of 2011 By: Decision Resources ... spending was a major target for cost cutting, and further economies can be expected in the coming months. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| more...	11/1/2011	$4,600.00
Will Big Pharma Find Success in Generics? By: Decision Resources ... to take advantage of generics opportunities in both established and emerging pharmaceutical markets. These endeavors offer the potential of a top-line boost in revenues at a time when patent cliffs loom and innovative brand sales ... \| more...	11/1/2011	$4,600.00
Special Report: Current Treatments, Unmet Needs, and Opportunities in Treating Pediatric Crohn’s Disease By: Decision Resources ... current treatment. With only one approved therapy for children-Janssen Biotech/Merck's Remicade (infliximab)-this market presents a reasonable opportunity for drug developers. Questions Answered Pediatric CD is a rare disorder. What is the total diagnosed prevalent population ... \| more...	11/1/2011	$9,200.00
Market Access in the United States: An Uncertain Outlook By: Decision Resources ... population covered by employer-sponsored insurance has declined significantly. The quality of benefits is under pressure as payers increase cost sharing and implement policies to restrict the use of high-priced drugs. Healthcare reform promises to boost ... \| more...	11/1/2011	$4,600.00
How Big Pharma’s R&D Focus Is Changing By: Decision Resources ... an example, Roche has been hugely successful but came to realize that the biologics and innovation culture from Genentech were its primary growth drivers. Predictably, Roche decided to acquire and integrate Genentech into its operations. ... \| more...	11/1/2011	$4,600.00
Innovative Technologies and Platforms: Fueling the Engines of Drug Discovery By: Decision Resources ... of distinct technologies, from novel chemistries to computational approaches to transgenic animal models. In some cases, these companies have devised alternative business and partnering models that enable them to strike alliances to test and validate ... \| more...	11/1/2011	$4,600.00
Diagnostics for the Developing World: Supporting Global Citizenship By: Decision Resources ... and systemic instability are ever-present barriers to accessibility. Multitudes of opportunities exist in diagnostics development, particularly to address the detection of neglected tropical diseases (NTDs) in developing countries. Companies of all sizes are beginning to ... \| more...	10/1/2011	$4,600.00
Special Report: Evolving Patterns and Unmet Needs in the TB Population in Developing and Developed Markets By: Decision Resources ... will decline over the coming decade as public health improves and the use of HAART (highly active antiretroviral therapy) becomes more widespread, TB will continue to be a public health concern and multidrug resistance a ... \| more...	10/1/2011	$9,200.00
Pharmaceutical Market Access in Europe: The Barriers Keep On Rising By: Decision Resources ... controlled, innovation is a key factor in determining price and reimbursement status, and launch delays can be substantial. By comparison, Germany and the United Kingdom were historically free pricing markets, characterized by relatively high prices ... \| more...	10/1/2011	$4,600.00
Special Report: The Pricing and Reimbursement Environment for Respiratory Disease Therapies By: Decision Resources ... front and center as the subjects of efforts to improve patient outcomes while containing costs to health systems. Governments and other payers are compelled to invest substantial resources in the management of these disorders. At ... \| more...	10/1/2011	$4,600.00
Recalibrating Goals Can Lead to Better Outcomes in Academic/Industry Biomarker and Diagnostics Collaborations By: Decision Resources ... of therapeutic areas, but some are much more common than others. Which therapeutic areas have the greatest number of biomarker/diagnostics collaborations? Industrial science and academic science have fundamentally different orientations, as well as different cultures ... \| more...	10/1/2011	$4,600.00
Novel Drug Targets and Strategies for Asthma and Chronic Obstructive Pulmonary Disease By: Decision Resources ... Patients with severe corticosteroid-refractory asthma are desperate for novel treatment options, a need that creates opportunities for development of innovative therapies that target novel mechanisms of action. Opportunities are also available for COPD drugs that ... \| more...	9/1/2011	$4,600.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Title Index: # | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

MarketResearch.com

Our People

On The Web

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: Monday - Thursday: 5:30am - 7:00pm EST

Fridays: 5:30am - 6:00pm EST